Russia approved its COVID-19 vaccine in August without starting phase 3 clinical trials. The breakthrough was seen as a public relations victory for Vladimir Putin and Russian drug companies.
However, the main developer of Sputnik V, in an exclusive interview with CNN, acknowledges that so far only 6,000 participants have received two doses.
In addition, it ensures that its use is not recommended in people over 60 years of age or people with diseases.
